First Longitudinal Study: Ketamine-Assisted Psychotherapy in Youth (US, 2026)

First Longitudinal Evidence: Ketamine-Assisted Psychotherapy in Adolescents and Young Adults

The first quantitative longitudinal study of ketamine-assisted psychotherapy (KAP) in adolescents and young adults in the United States reports promising reductions in depression and suicidality, with a favorable safety profile. Published on September 21, 2026 (OpenAlex record), the study followed 19 patients aged 14–24 at a single community outpatient clinic, each completing at least three KAP sessions. Over a median follow-up of 5.6 months (mean 10.1, range 0.9–36.4), patients showed a steady decline in depressive symptoms (Beck Depression Inventory-II, BDI-II) by 0.65 points per visit and a similar trend for anxiety (Hamilton Anxiety Rating Scale, HAM-A). Notably, 68.4% of participants and their physicians reported overall benefit, and marked reductions in suicidality were observed in at-risk individuals. This study represents the first systematic, real-world data on KAP for youth, a demographic often excluded from psychedelic research.

Mechanism and Context: Addressing Complex Youth Mental Health Needs

Ketamine, an NMDA receptor antagonist, has established rapid-acting antidepressant effects in adults, but its use in younger populations remains underexplored. The study's participants represented a diagnostically complex group, reflecting the real-world heterogeneity of adolescent mental health crises—often characterized by treatment resistance and comorbidities. The KAP protocol integrated family therapy elements, aiming to leverage ketamine's neuroplastic and dissociative properties alongside psychotherapeutic support. The observed reduction in depression and suicidality aligns with ketamine's hypothesized mechanism of enhancing synaptic plasticity and disrupting maladaptive cognitive patterns, though the precise neurodevelopmental effects in adolescents are not fully understood. Importantly, the study's real-world, outpatient setting and inclusion of family systems therapy provide a concrete model for future research and clinical practice, rather than the highly controlled environments typical of early-phase trials.

Policy and Research Implications: Informing Future Trials and Access Debates

The findings provide foundational evidence supporting the feasibility and tolerability of KAP in youth, informing the design of future randomized controlled trials (RCTs) and potentially influencing regulatory perspectives. Currently, ketamine is FDA-approved for anesthesia and, in its esketamine form, for treatment-resistant depression in adults; off-label use for psychiatric indications in youth is rare and controversial. This study's documentation of safety—no hospitalizations, substance misuse, or neurological harm over 167 sessions—may prompt institutional review boards (IRBs) and funders to reconsider age-based exclusions in psychedelic research. Furthermore, the observed benefit in a diagnostically complex, community-based cohort challenges the assumption that only highly selected, low-risk youth should be eligible for early-phase trials. For policymakers, the study underscores the urgent need for evidence-based alternatives in adolescent mental health, given rising rates of depression and suicide and frequent failure of conventional treatments. However, regulatory change will likely hinge on larger, controlled studies with longer follow-up and more diverse populations.

Risks, Unknowns, and Limitations: Interpreting the Early Signals

The main limitations of the study are its small sample size (n=19), lack of a control group, and single-site design, which restrict generalizability. While ketamine was well tolerated overall, with nausea as the only notable adverse event (5.4% of sessions), the study's follow-up period—though longer than most—remains limited in capturing rare or delayed adverse effects, especially in neurodevelopmentally sensitive populations. No evidence of substance misuse or neurological harm was observed, but the sample and duration are insufficient to rule out these risks. The absence of a placebo or active comparator also leaves open the possibility of expectancy effects or regression to the mean accounting for some observed improvements. In addition, the real-world, diagnostically diverse sample, while a strength for ecological validity, complicates attribution of benefit to KAP versus other concurrent interventions. A non-obvious concern is that positive early data could prompt premature clinical adoption or off-label use in youth before robust safety and efficacy evidence accumulates, a pattern seen in other areas of child psychiatry.

Looking Ahead: Building the Evidence Base for Psychedelic Therapies in Youth

The study establishes a precedent for systematic, quantitative research on KAP in adolescents and young adults and is likely to catalyze further controlled trials in this population. Future studies should prioritize larger, multisite designs, inclusion of control groups, and longer-term follow-up to assess durability of benefit and rare adverse events. Given the ongoing adolescent mental health crisis and the limitations of current treatments, the field faces a delicate balance: accelerating research to address urgent needs while maintaining rigorous safety standards and avoiding premature clinical adoption. The integration of family therapy and real-world clinical settings, as demonstrated here, may offer a pragmatic model for both research and eventual service delivery. As regulatory agencies and ethics committees consider expanding access to psychedelic therapies for youth, this study's findings will serve as an important, though preliminary, reference point.

How we research / reviewed by Dr. Jamie L. Carter, MD, MSc, child & adolescent psychiatrist, on 2026-09-23.